Response to Narayanan et al's "Adverse events in cemiplimab therapy for locally advanced or metastatic cSCC: A global propensity-matched retrospective cohort study"

J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03104-9. doi: 10.1016/j.jaad.2024.08.085. Online ahead of print.

Author

Serena Yun-Chen Tsai¹

Affiliation

¹ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ytsai3@mgh.harvard.edu.

PMID: 39522725
DOI: 10.1016/j.jaad.2024.08.085

No abstract available

Keywords: cutaneous squamous cell carcinoma; immune check inhibitor; oncology; safety.

Publication types

Letter